There’s good news for the Duchenne community as Lilly and Precision Biosciences announced a large investment in a genome editing platform of which Duchenne is one of the genetic disorders they will focus on. This research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets.
“Gene-edited therapies are emerging as a promising approach to help patients afflicted with genetic conditions,” said Ruth Gimeno, Ph.D., vice president of diabetes and metabolic research at Lilly. “We look forward to working closely with Precision’s scientific team and leveraging their platform to develop and deliver breakthrough medicines for untreated genetic disorders.”
“This collaboration with Precision BioSciences represents another milestone in the realization of our vision to create medicines with transformational potential, using new therapeutic modalities such as gene editing to tackle targets and indications which were previously undruggable,” added Andrew Adams, Ph.D., vice president of new therapeutic modalities at Lilly.
“We look forward to working with Lilly to leverage our deep understanding of in vivo gene editing and experience with ARCUS to develop new therapies, including a potentially transformative treatment for Duchenne muscular dystrophy,” said Derek Jantz, chief scientific officer and co-founder of Precision BioSciences. “Collaborating with Lilly, a global healthcare leader with strong clinical and commercial experience in difficult-to-treat diseases, will help us accelerate our work aimed to solve genetic diseases with unique editing challenges.”
Lilly Canada is the Canadian affiliate of Eli Lilly and Company, one of the world’s largest research-based pharmaceutical companies. The affiliate was founded in 1938 as a result of a collaboration between Eli Lilly and Company and Banting and Best, which produced the world’s first commercially available insulin. Their work has broadened, and they now focus on diabetes, cancer, immunology, pain and neurodegeneration.
About Precision Biosciences
Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical-stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and infectious diseases.